EN DE
Watch Genscript Biotech Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Genscript Biotech Corp (1548) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Genscript Biotech Corp stock HK$22.06, price HK$30.38, that is 27.4% below the price, quality 55 out of 100. Rating: overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · ISIN KYG3825B1059

GB Genscript Biotech Corp logo Some data Nov 14, 2026

Genscript Biotech Corp

1548 · HK

Expensive (fair value 27% below the price), but solid company and rising price: meets 2 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Generates free cash flow 
Recent news very positive 
Quality 55/100 
Mixed Growth (revenue YoY +61.4 %/yr in USD) 
Mixed vs. peers (6/12) 
Some data 
Revenue last quarter 22% below a year ago. 
Fair value HK$22.06 · Overvalued 
Loss-making · -75.4% net margin (TTM) 
Narrow moat 21/100 · thin data

Main risks:

🚩US regulatory scrutiny over China ties🚩Rivals like Twist Bioscience or Synbio Technologies
Watch Genscript Biotech Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$49.14 HK$8.23 Fair Value HK$22.06 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range HK$8.23 – HK$49.14 · fair‑value band HK$13.22 – HK$41.48 · the HK$30.38 price screens above the HK$22.06 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Genscript Biotech in your weekly email

Every Wednesday you see whether Genscript Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.

Show moreShow less

It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application.

The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform.

The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering.

It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease.

In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank.

It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.

Stock analysis

Genscript Biotech Corp (1548) currently trades at HK$30.38, while our model-based Fair Value estimate is HK$22.06, 27% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of HK$22.06 per share, and 0 of the 13 models we run sit above the HK$30.38 price.

Bear case: the Earnings-Based group reads lowest at HK$7.39, and 13 of the 13 models stay below the price. Data coverage for this calculation is medium.

Scenario range: HK$13.22 (bear) to HK$41.48 (bull), the price of HK$30.38 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Genscript Biotech Corp reported revenue of $960M in FY2025 versus $511M in FY2021, a compound +17.1%/yr. Reported net income was −$533M in FY2025.

Key figures

Market cap HK$69.3B (≈ $8.8B) Mid · P/E ex one-offs 36.8 · P/S ratio 85.3 · Net margin −55.5% · Return on equity −15.3% · Return on assets (EBIT) −6.6% (5-year average) · Operating margin 12.3% · Revenue (TTM) $845M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).

What moves the price

The share trades about 38% below its 52-week high and 187% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −27%, 1548 screens richer than that median.

Fair Value models

Bear HK$13.22 Fair Value HK$22.06 Bull HK$41.48
Price HK$30.38 · Downside -27.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$14.09 HK$21.13 HK$42.85 76
Growth DCF HK$13.26 HK$24.18 HK$41.63 76
EPV HK$6.49 HK$7.39 HK$8.16 74
All 13 models by family
DCF Models
FCF DCF HK$14.09 HK$21.13 HK$42.85 76
5Y Revenue Exit HK$9.96 HK$16.19 HK$29.17 70
5Y EBITDA Exit HK$13.22 HK$22.77 HK$41.48 72
10Y Revenue Exit HK$11.07 HK$22.06 HK$28.60 66
10Y EBITDA Exit HK$13.65 HK$28.82 HK$55.00 64
Earnings-Based
EPV HK$6.49 HK$7.39 HK$8.16 74
Multiples
EV/EBIT HK$10.80 HK$14.53 HK$18.26 66
EV/EBITDA HK$11.49 HK$15.46 HK$19.42 67
EV/Revenue HK$6.53 HK$9.50 HK$12.47 53
Asset-Based
NCAV (Graham) HK$0.3700 HK$0.5600 HK$0.7000 55
Growth DCF
Growth DCF HK$13.26 HK$24.18 HK$41.63 76
Rev-Margin DCF HK$10.90 HK$18.44 HK$34.26 69
Economic Profit
ROIC Compounder HK$6.49 HK$7.39 HK$8.16 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 55/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 79
Are margins and returns getting better?
Cashflow 89
Do the profits arrive as real cash?
Financial strength 82
Debt, balance sheet and risk of trouble
Investment 21
Does it invest with discipline instead of growing at any price?
Low Volatility 38
How calm the share price moves, does not count
Price momentum 93
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 76
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−52.3% (2020) → 26.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +16.0% a year for the price and +10.9% for the forecasts.
Forecast 2026 (sales)−7.3%
Forecast 2027 (sales)+23.5%
Projected 2028 (sales)+20.8%
Projected 2029 (sales)+18.1%
Projected 2030 (sales)+15.4%

1548 screens overvalued: fair value 27% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare Genscript Biotech Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 55 · Top 25%
Fair Value upside −27.4% · Below median
Profitability
Return on assets −11.0% · Above median
Net margin (12 months) −75.4% · Bottom 25%
Operating margin (12 months) 12.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −22.1% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.23× · Cheaper than median
P/S (12 months) 10.45× · Pricier than median
Price / free cash flow (fiscal year) 36.5× · Pricier than median
EV/EBITDA 44.9× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs 1548
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs 1548
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs 1548
Genmab A/S GMAB kr 3,448 kr 3,793 +10% vs 1548
argenx SE ARGX $960.04 $908.40 −5% vs 1548
CSL Limited CSL A$202.52 A$185.51 −8% vs 1548
Moderna, Inc MRNA $223.37 $139.99 −37% vs 1548
Revolution Medicines, Inc RVMD $172.29 $88.78 −48% vs 1548
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs 1548
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs 1548

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genscript Biotech Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Genscript Biotech Corp Fair Value". https://www.fairvalue-calculator.com/stock/1548

Frequently asked questions

Is Genscript Biotech Corp (1548) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of HK$22.06 versus a price of HK$30.38, about 27% lower (overvalued).
What is the fair value of 1548?
Our model-based fair value for Genscript Biotech Corp is HK$22.06 (as of Nov 14, 2026), built from audited fundamentals. The current price: HK$30.38.
What is the quality score of 1548?
Genscript Biotech Corp has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genscript Biotech Corp (1548)?
Our model-based price target is the fair value of HK$22.06 (as of Nov 14, 2026) from 13 valuation models. Cautious scenario HK$13.22, optimistic scenario HK$41.48. It is a calculation from audited fundamentals, not an analyst target.
What is the Genscript Biotech Corp stock forecast for 2026?
Our models put fair value at HK$22.06, about 27% lower versus a price of HK$30.38 (overvalued). Cautious scenario HK$13.22, optimistic scenario HK$41.48. The calculation is refreshed regularly with new filings.
What is the revenue of Genscript Biotech Corp (1548)?
Genscript Biotech Corp reported trailing-twelve-month revenue of about $845M (latest available figure, as of Nov 14, 2026).
What growth is priced into Genscript Biotech Corp (1548)?
For today's price to be fair in a discounted-cash-flow model, Genscript Biotech Corp would have to grow free cash flow by 18.8 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 19.7 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of 1548 use?
Our models discount Genscript Biotech Corp at 9.8 %: a base by market capitalisation (mid), damped by beta 0.81, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Genscript Biotech Corp that is +18.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Genscript Biotech Corp (1548) delivered so far?
Over the past 5 years revenue at Genscript Biotech Corp grew 19.7 % a year. The price currently implies free-cash-flow growth of +18.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Genscript Biotech Corp (1548) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Genscript Biotech Corp (+18.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Genscript Biotech Corp (1548)?
The free-cash-flow yield on the price is 2.86 %: that much free cash flow Genscript Biotech Corp produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Genscript Biotech Corp (1548)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genscript Biotech Corp it is HK$22.06 per share (as of Nov 14, 2026), against a price of HK$30.38. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Genscript Biotech Corp stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 1548 trades above its calculated fair value: price HK$30.38, fair value HK$22.06, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1548?
No. The price is what the market pays today (HK$30.38); the fair value is what the company's own numbers justify (HK$22.06). For Genscript Biotech Corp the two are HK$8.32 per share apart. That gap is exactly why we show both numbers side by side.
How much is Genscript Biotech Corp worth?
The market values Genscript Biotech Corp at about HK$69.3B (market capitalisation, as of Nov 14, 2026). Per share that is HK$30.38; our models calculate a fair value of HK$22.06 per share.
What do the bullish and bearish scenarios say about 1548?
Our models span a range for Genscript Biotech Corp: cautious scenario HK$13.22, base HK$22.06, optimistic HK$41.48 per share (as of Nov 14, 2026, price HK$30.38). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genscript Biotech Corp (1548)?
Balance-sheet figures for Genscript Biotech Corp (as of Nov 14, 2026): return on equity −15.3%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 1548 from its 52-week high?
Genscript Biotech Corp trades at HK$30.38, about 38% below its 52-week high of HK$49.14 and 187% above the low of HK$10.60 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$22.06 is for.
Which stocks are comparable to Genscript Biotech Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genscript Biotech Corp stock attractive at the current price?
The data as of Nov 14, 2026: price HK$30.38, calculated fair value HK$22.06 (−27%), Quality Score 55/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1548 calculated?
We run Genscript Biotech Corp through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of HK$22.06 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Genscript Biotech Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genscript Biotech Corp (1548)?
The closing price on Nov 13, 2026 was HK$30.38. Our model-based fair value is HK$22.06, about 27% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genscript Biotech Corp right now?
The model range is unusually wide (HK$13.22 to HK$41.48). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Genscript Biotech Corp

How large is the market capitalisation of Genscript Biotech Corp (1548)?
The market capitalisation of Genscript Biotech Corp is HK$69.3B (≈ $8.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Genscript Biotech Corp (1548) excluding one-off items?
Excluding one-off items, the price-to-earnings ratio of Genscript Biotech Corp is 36.8 (fiscal year 2025, the reported result was a loss).
What is the P/S ratio of Genscript Biotech Corp (1548)?
The price-to-sales ratio of Genscript Biotech Corp is 85.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Genscript Biotech Corp (1548)?
The net margin of Genscript Biotech Corp is −55.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genscript Biotech Corp (1548)?
The return on equity (ROE) of Genscript Biotech Corp is −15.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genscript Biotech Corp (1548)?
On an EBIT basis the return on assets of Genscript Biotech Corp is −6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genscript Biotech Corp (1548)?
The operating margin of Genscript Biotech Corp is 12.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genscript Biotech Corp (1548)?
Revenue at Genscript Biotech Corp is down 22.1% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Genscript Biotech Corp (1548) carry?
The net debt of Genscript Biotech Corp is $116M (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Genscript Biotech Corp in the live analysis

One click puts Genscript Biotech Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.